Aditum Bio

Joe Jimenez
Biotech

Aditum finds twist on old idea, paying $10M for BTK inhibitor

The outlay gives Aditum Bio near-global rights to a BTK inhibitor, with a twist, that is in development in diseases including rheumatoid arthritis.
Nick Paul Taylor Apr 28, 2023 6:11am
Parachute

Before exiting J&J, Gorsky lands on Apple board—Chutes & Ladders

Nov 12, 2021 9:30am
Parachute

Joe Jimenez's Ancora Bio poaches Sage CMO to revive Taisho drug

Nov 8, 2021 10:50am
Joe Jimenez headshot

Aditum launches Ancora with rights to Taisho's depression drug

Jul 1, 2021 11:51am
Joe Jimenez headshot

Novartis alums Jimenez, Fishman unveil their next act

Nov 2, 2020 7:00am